AR and prostate cancer: While PPARγ ligands suppress AR activation in AR-positive, castration-sensitive prostate cancers via mechanisms that are independent of PPARγ, ligand-induced activation of PPARγ increases AR signaling in AR-positive, castration-resistant prostate cancer cells.